8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jan 28, 2015)

Filed January 28, 2015For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on January 28, 2015, to announce its financial results for the fourth quarter and full year ended December 31, 2014. The report incorporates by reference a press release issued on the same date, which contains the detailed financial performance and operational updates. Investors should refer to the attached press release (Exhibit 99.1) for the specific financial figures and management commentary regarding the company's performance, including any updates on its product pipeline, sales, and outlook.

Key Highlights

  • 1Vertex Pharmaceuticals reported its Q4 and full-year 2014 financial results via an 8-K filing.
  • 2The 8-K references a press release dated January 28, 2015, which contains the detailed financial information.
  • 3Investors are directed to the attached press release (Exhibit 99.1) for specific financial data.
  • 4The filing pertains to the period ending December 31, 2014.
  • 5The information is incorporated by reference, meaning the press release is considered part of the filing.
  • 6This report serves as an official notification of the company's financial performance for the relevant periods.

Frequently Asked Questions

The primary purpose of this 8-K filing is to publicly announce and provide access to Vertex Pharmaceuticals' consolidated financial results for the fourth quarter and the full fiscal year ended December 31, 2014.

The specific financial details, including revenue, earnings, and other performance metrics, are contained within the press release dated January 28, 2015, which is attached as Exhibit 99.1 to this 8-K filing and is incorporated by reference.

The financial results reported cover the three-month and twelve-month periods that ended on December 31, 2014.

No, the information set forth in Exhibit 99.1 (the press release) is generally not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, and therefore is not subject to the liabilities of that section, unless expressly incorporated by reference into another filing.